Norwegian Contrasts
LATEST NEWS

Annual General Meeting to be held 21 June 2018
8 June 2018
The annual general meeting of IC Targets is to be held at Oslo Science Park on 21 June 2018. Links to Notice is found below.
Notice of AGM (Norwegian only) download
Annual report 2017 (Norwegian only) download

Partnership with be imaging GmbH
27 April 2018
IC Targets announces that it has signed an agreement with b.e. imaging for the development of a mangafodipir MRI contrast agent. For more information please read the enclosed press release.

License agreement with GE HealthCare
22 August 2017
Proceeds from the private placement of shares completed in August 2017 provided IC Targets with funding for entering into an exclusive world wide license agreement with GE Healthcare (GEHC) for use of mangafodipir tridosium ("mangafodipir") in vivo imaging. This agreement with GEHC is a key element of the revised business plan of IC Targets. With the agreement, the company has obtained access to the original contrast agent for use in clinical studies and subsequently also for commercialization of the patented proprietary cardiovascular indication.

Magnetic resonance imaging (MRI) is the fastest growing imaging modality, with more than 35 million procedures being performed in 2015 using Contrast Agents (CAs). All marketed MRI CAs contain the rare earth metal gadolinium (Gd). In recent years, regulatory health authorities have raised concerns about the use of Gd-based CAs (GBCAs). Thus, access to mangafodipir also provides IC Targets with a short term business opportunity within the original indication liver and pancreas MRI. Presently, manufacturing and distribution agreements are being explored.
WHAT WE DO AT IC TARGETS

During MRI scans it is sometimes necessary to give the patient a substance to improve the clarity of the images. Such substances are called contrast agents and allow doctors to better identify disease. IC Targets develops a contrast agent helping cardiologists to select the patients benefiting from reopening of cardiac blood veins (revascularisation). This may lead to better care and reduced risk of heart failure.

The company is based in Oslo, Norway, the global home of modern contrast agents.